Hepatitis News : High Cure Rates in Hep C Clinical Trials Don’t Lead to Real World Success
A Smart + Strong Site
Subscribe to:
Hepatitis E-newsletter
Join Us:

Back to home » Hepatitis News » December 2012


emailprint

December 17, 2012

High Cure Rates in Hep C Clinical Trials Don’t Lead to Real World Success

Promising results in clinical trials of hepatitis C virus (HCV) therapies are tempered by the fact that many barriers stand in the way of successfully treating and curing the disease outside of controlled research settings and in real world clinical practices, a new study has found. A largely Texas-based consortium of researchers conducted a literature review, finding 25 studies with data about patient experience with hep C antiviral treatment independent of clinical trials. They published their paper in General Hospital Psychiatry.

The researchers found that clinicians only considered 19 percent of hep C patients and 16 percent of coinfected patients eligible for treatment. Just 13 and 11 percent of hep C patients, respectively, actually completed treatment, while a respective 3 and 6 percent achieved a sustained virologic response (SVR, considered a cure).

The main barriers to treatment were psychiatric disorders, substance use, medical ineligibilities such as severe anemia and thrombocytopenia (low red blood cells), or liver disease that was either too advanced or not advanced enough to warrant treatment.

The researchers wrote, “Only by systematically observing and addressing potentially solvable medical and psychological barriers to treatment will more patients be enrolled in and complete HCV therapy.”

To read the study abstract, click here.

Search: Cure, sustained virologic response, SVR, hep C, hepatitis C, HCV, clinical trials, real world success, research, treatment, General Hospital Psychiatry, coinfected, psychiatric disorders, substance use, anemia thrombocytopenia, low red blood cells, liver disease, therapy, antiviral.


Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
Current Issue
Forums
Poll
Blogs
Hep TV
Calendar
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
Transmission
Prevention
Treatment
• Hepatitis B
Transmission
Prevention
Treatment
• Hepatitis C
Transmission
Prevention
Treatment
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
TALK TO US
Tell us what you think
Poll
Are you a member of the Hep forums?
Yes
No


Survey
Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.